The pharmacology of human appetite expression.
The discovery of the adiposity signal leptin a decade ago revolutionised our understanding of the hypothalamic mechanisms underpinning the central control of ingestive behaviour. Subsequently, the structure and function of various hypothalamic peptide systems (Neuropeptide Y (NPY), Orexins, Melanocortins, Cocaine and Amphetamine Regulating Transcript (CART), Galanin/Galanin Like Peptides (GALP) and endocannabinoids) have been characterised in detail in rodent models. The therapeutic benefit of targeting these systems remains to be discovered. More is becoming known about the pharmacological potential of peripheral, meal-induced, episodic endogenous peptides. Hormones such as Cholecystokinin (CCK), Gastrin Releasing Peptides (GRP), Glucagon-Like Peptide I (GLP-1) Enterostatin, Amylin, Peptide YY (PYY) and Ghrelin are released prior to, during and/or after a meal, controlling intake and subjective feelings of appetite (hunger and satiety). In addition, there is an expanding body of literature detailing the effects of a wide variety of drugs on human appetite and food intake. Some of these drugs act upon CNS monoamine systems such as Serotonin (5-HT). Dopamine (DA) and Noradrenaline (NA), have long been implicated in appetite regulation. Detailed examination of both the effect of agonising endogenous gut peptide systems and the effect of various monoaminergic drugs on the expression of human appetite can provide a greater understanding of mechanisms underpinning normal appetite regulation. However, such an understanding must be based on knowledge of the effect of the treatment on meal size, eating rate, meal pattern, food choice and the subjective experience of appetite flux (hunger and satiety), and notjust food intake.
Halford
Jason C G
JC
Kissileff Laboratory for the Study of Human Ingestive Behaviour, Department of Psychology, University of Liverpool, Eleanor Rathbone Building, Bedford Street South, Liverpool, L69 7ZA, UK. j.c.g.halford@liv.ac.uk
Cooper
Gillian D
GD
Dovey
Terence M
TM
D001066:Appetite / Q000187:drug effects / Q000502:physiology; D001069:Appetite Regulation / Q000502:physiology*; D002986:Clinical Trials as Topic; D004064:Digestive System / Q000378:metabolism; D004435:Eating; D005768:Gastrointestinal Hormones / Q000378:metabolism; D006801:Humans; D006815:Hunger / Q000502:physiology; D007031:Hypothalamus / Q000378:metabolism; D009479:Neuropeptides / Q000502:physiology; D018377:Neurotransmitter Agents / Q000502:physiology; D010600:Pharmacology; D012528:Satiety Response / Q000502:physiology
D005768:Gastrointestinal Hormones; D009479:Neuropeptides; D018377:Neurotransmitter Agents